From Phase Ii Studies to Hta Submissions: Optimal Use of Evidence for Informed Decisions

Value in Health - United Kingdom
doi 10.1016/j.jval.2015.09.2779
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

PHP159 Proposed and Actual Bureaucratic Burden of HTA Submissions to the Industry- Case Studies From Germany and UK

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Issues in the Selection of Comparators for Regulatory and Hta Submissions

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Prm106 - Advanced Nma Techniques in Nice Hta Submissions

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Informed Consent to Rationing Decisions

Milbank Quarterly
Health PolicyPublic HealthOccupational HealthEnvironmental
1993English

Risk-Informed Decisions for Epidemics

Journal of Decision Systems
SoftwareManagement Information Systems
2016English

Pcn274 - Time to Price Change Following Hta Decisions

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

A Framework to Guide the Optimal Development and Use of Real-World Evidence for Drug Coverage and Formulary Decisions

Journal of Comparative Effectiveness Research
Health Policy
2018English

Php235 - Indirect Treatment Comparisons (Itc) for Hta in Europe – Understanding Requirements for Industry Submissions

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Gender Gaps in the Evaluation of Research: Evidence From Submissions to Economics Conferences

SSRN Electronic Journal
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy